独立董事提名人声明与承诺 提名人江西天新药业股份有限公司董事会,现提名刘桢女士、杨 延莲女士、刘路遥先生为江西天新药业股份有限公司第三届董事会独 立董事候选人,并已充分了解被提名人职业、学历、职称、详细的工 作经历、全部兼职、有无重大失信等不良记录等情况。被提名人已同 意出任江西天新药业股份有限公司第三届董事会独立董事候选人(参 见该独立董事候选人声明)。提名人认为,被提名人具备独立董事任职 资格,与江西天新药业股份有限公司之间不存在任何影响其独立性的 关系,具体声明并承诺如下: 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、规章及其他规范性文件,具有 5年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人刘桢女士、杨延莲女士已经参加培训并取得证券交易所 认可的相关培训证明材料。被提名人刘路遥先生承诺在本次获得提名 后，将参加上海证券交易所举办的独立董事培训。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求: (一)《中华人民共和国公司法》关于董事任职资格的规定: (二)《中华人民共和国公务员法》关于公务员兼任职务的规定(如 适用); (三 ...

证券代码：603235 证券简称：天新药业 公告编号：2023-029 江西天新药业股份有限公司 关于董事会、监事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江西天新药业股份有限公司（以下简称"公司"）第二届董事会、监事会任 期将于 2023 年 11 月 19 日届满，公司依据《公司法》《证券法》《上海证券交 易所股票上市规则》及《公司章程》等相关规定，开展董事会、监事会换届选举 工作。公司于 2023 年 10 月 27 日召开第二届董事会第十六次会议，审议通过了 《关于公司董事会换届选举暨提名第三届董事会非独立董事候选人的议案》《关 于公司董事会换届选举暨提名第三届董事会独立董事候选人的议案》；同日，公 司召开第二届监事会第十四次会议，审议通过了《关于公司监事会换届选举暨提 名第三届监事会非职工代表监事候选人的议案》。上述议案尚需提交公司 2023 年第一次临时股东大会审议。 现将本次董事会、监事会换届选举情况说明如下： 一、 董事会换届情况 公司第三届董事会由 9 名董事组成，其中非独立董事 6 ...

本人刘桢,已充分了解并同意由提名人江西天新药业股份有 限公司第二届董事会提名为江西天新药业股份有限公司第三届 董事会独立董事候选人。本人公开声明,本人具备独立董事任职 资格,保证不存在任何影响本人担任江西天新药业股份有限公司 独立董事独立性的关系,具体声明并承诺如下: 独立董事候选人声明与承诺 一、本人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、部门规章及其他规范性文件,具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 本人已经参加培训并取得证券交易所认可的相关培训证明 材料。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求: (一)《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的 规定(如适用); (三)中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定; (四)中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退(离)休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定（如适用）; (五)中共 ...

证券代码：603235 证券简称：天新药业 公告编号：2023-027 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司（以下简称"公司"） 2023 年第三季度经营数据（未经审计）公告如下： 江西天新药业股份有限公司 关于 2023 年第三季度经营数据的公告 2、主营业务分渠道情况 单位：元 币种：人民币 | 产品分类 | 2023 | 年 7-9 | 月收入 | 2022 | 年 7-9 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | --- | | 直销 | | 204,765,152.43 | | | 296,121,213.87 | | -30.85% | | 经销 | | 159,084,562.40 | | | 199,605,644.78 | | -20.30% | | 小计 | | 363,849,714.83 | | ...

江西天新药业股份有限公司独立董事 关于第二届董事会第十六次会议相关事项的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易 所股票上市规则》《上海证券交易所上市公司自律监管指引第1号 -- 规范运作》 《上市公司独立董事管理办法》以及《江西天新药业股份有限公司章程》（以下 简称《公司章程》）《江西天新药业股份有限公司独立董事工作制度》等相关法 律法规、规章制度的规定,我们作为公司的独立董事,经认真审阅公司第二届董 事会第十六次会议相关文件,听取相关说明,基于独立、客观、公正的判断立场， 发表独立意见如下: 一、关于公司修订《独立董事工作制度》的独立意见 经认真审阅相关资料,基于独立、客观判断,我们认为: 公司本次修订《独立董事工作制度》是为了进一步完善公司治理结构,促进 公司规范运作,维护公司整体利益,更好的保障全体股东特别是中小股东的合法 权益不受损害。本次修订内容符合法律、法规和规范性文件的最新规定,符合公 司实际情况，不存在损害股东利益尤其是中小股东利益的情形。 综上,我们同意修订《独立董事工作制度》的议案,并同意将该议案提交股 东大会审议。 二、关于董事会换届选举暨提名第三届 ...

中信证券股份有限公司 关于江西天新药业股份有限公司 变更部分募集资金投资项目的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江西天 新药业股份有限公司（以下简称"天新药业"或"公司"）首次公开发行股票并 上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所上市 公司自律监管指引第 11 号——持续督导》《上市公司监管指引第 2 号——上市 公司募集资金管理和使用的监管要求（2022 年修订）》《上海证券交易所上市公 司募集资金管理办法》《上海证券交易所上市公司自律监管指引第 1 号——规范 运作》等有关规定，对天新药业变更部分募集资金投资项目的事项进行了专项核 查，核查情况如下： 一、变更部分募集资金投资项目的概述 （一）募集资金到位情况 经中国证券监督管理委员会《关于核准江西天新药业股份有限公司首次公开 发行股票的批复》（证监许可[2022]1220 号）核准，公司首次公开发行人民币普 通股（A 股）股票 43,780,000 股，每股发行价格 36.88 元/股，募集资金总额为 161,460.64 万元，扣除发行费用后募集资金净额为 151,723.31 万元。上述 ...

证券代码：603235 证券简称：天新药业 公告编号：2023-030 江西天新药业股份有限公司 关于变更部分募集资金投资项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 原项目名称：1、"年产 1,000 吨维生素 A 项目"，调整项目方案，预计 一期项目投资金额调减至 43,206 万元，拟使用募集资金调减 20,000 万元；2、 "企业研究院项目"，调整项目方案，预计项目投资金额调减至 12,887万元，拟 使用募集资金调减 11,000 万元。 新项目名称："年产 6.677 万吨精细化学品项目"（以下简称"新项目"）， 由江西天新药业股份有限公司（以下简称"公司"）全资子公司宁夏天新药业有 限公司（以下简称"宁夏天新"）负责实施，预计项目投资金额 50,000万元，拟 使用募集资金 31,000 万元。 变更募集资金投向的金额：公司拟将"年产 1,000 吨维生素 A 项目"尚 未使用募集资金中的 20,000 万元、"企业研究院项目"尚未使用募集资金中的 11,000 万元用于建设新项目 ...

证券代码：603235 证券简称：天新药业 公告编号：2023-024 一、说明会类型 会议召开时间：2023 年 10 月 16 日(星期一)下午 15:00-16:00 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 江西天新药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 10 月 09 日(星期一)至 10 月 13 日(星期五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱 ir@txpharm.com 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 江西天新药业股份有限 ...

Financial Performance - Revenue for the first half of 2023 decreased by 9.73% to RMB 1,120,547,937.20 compared to the same period last year[5] - Net profit attributable to shareholders of the listed company decreased by 17.77% to RMB 329,956,160.32[5] - Basic earnings per share decreased by 26.47% to RMB 0.75[6] - Weighted average return on equity decreased by 11.19 percentage points to 7.81%[6] - Revenue for the period was 1,120,547,937.20 RMB, a decrease of 9.73% compared to the same period last year[80] - Net profit attributable to shareholders was RMB 330 million, down 17.77% compared to the same period last year[92] - Revenue for the first half of 2023 was RMB 1.121 billion, a decrease of 9.73% year-over-year[92] - The company's revenue from nutritional products was 1,053,876,315.45 RMB, with a gross margin of 37.89%, representing a decrease of 11.97% in revenue and a 4.40 percentage point decrease in gross margin compared to the previous year[76] - Revenue from B-vitamins was 980,187,143.87 RMB, with a gross margin of 39.87%, showing a decrease of 10.56% in revenue and a 4.10 percentage point decrease in gross margin compared to the previous year[76] - The company's total revenue was 1,102,324,478.47 RMB, with a gross margin of 37.51%, reflecting a decrease of 9.19% in revenue and a 4.90 percentage point decrease in gross margin compared to the previous year[76] - Domestic sales revenue was 450,389,400.82 RMB, with a gross margin of 38.00%, indicating a 3.24% increase in revenue but a 4.99 percentage point decrease in gross margin compared to the previous year[76] - Export sales revenue was 651,935,077.65 RMB, with a gross margin of 37.17%, showing a decrease of 16.16% in revenue and a 4.91 percentage point decrease in gross margin compared to the previous year[76] Cash Flow and Operating Activities - Cash flow from operating activities increased by 61.77% to RMB 401,420,301.67[5] - Net cash flow from operating activities increased by 61.77% to 401,420,301.67 RMB[80] - Net cash flow from investing activities was 29,091,940.48 RMB, compared to -66,761,791.88 RMB in the same period last year[80] - Financial expenses were -88,546,844.69 RMB, primarily due to increased interest from RMB and USD deposits[79] Assets and Liabilities - Total assets increased by 2.77% to RMB 4,809,368,353.09 compared to the end of last year[5] - Total assets as of June 30, 2023, amounted to 4,809,368,353.09, compared to 4,679,962,858.74 as of December 31, 2022[176] - Cash and cash equivalents increased to 2,363,328,253.22 as of June 30, 2023, from 2,069,864,246.58 as of December 31, 2022[176] - Accounts receivable decreased to 249,343,319.51 as of June 30, 2023, from 259,397,909.74 as of December 31, 2022[176] - Inventory decreased to 397,343,495.17 as of June 30, 2023, from 470,628,636.85 as of December 31, 2022[176] - Fixed assets decreased to 1,153,548,267.87 as of June 30, 2023, from 1,180,323,935.24 as of December 31, 2022[180] - Construction in progress increased to 190,737,514.27 as of June 30, 2023, from 122,640,615.79 as of December 31, 2022[180] - Intangible assets increased to 194,843,819.93 as of June 30, 2023, from 109,814,312.46 as of December 31, 2022[180] - Total current liabilities increased to 380,477,375.20 as of June 30, 2023, from 311,178,261.53 as of December 31, 2022[180] - Accounts payable decreased to 70,058,333.62 as of June 30, 2023, from 108,545,290.36 as of December 31, 2022[180] - Employee benefits payable decreased to 54,777,450.21 as of June 30, 2023, from 99,117,377.05 as of December 31, 2022[180] - The company's monetary funds increased to 2,326,933,446.22 RMB as of June 30, 2023, compared to 2,054,246,268.02 RMB at the end of 2022[182] - Trade receivables decreased slightly to 257,022,544.27 RMB from 261,588,692.80 RMB over the same period[182] - Inventory levels decreased to 406,746,915.52 RMB from 454,808,652.06 RMB[182] - Prepayments increased significantly to 88,675,349.92 RMB from 49,814,225.84 RMB[182] - The company's total liabilities increased to 727,286,341.51 RMB from 621,981,219.02 RMB[197] - Total owner's equity increased to 4,082,082,011.58 RMB from 4,057,981,639.72 RMB[197] - Retained earnings grew to 1,443,478,691.15 RMB from 1,424,346,330.83 RMB[197] - The company's total assets increased to 4,809,368,353.09 RMB from 4,679,962,858.74 RMB[197] - Total current assets increased slightly to 3,177,105,069.57 from 3,171,456,023.36[198] - Long-term equity investments rose significantly to 145,938,705.95 from 50,938,705.95[198] - Fixed assets decreased to 1,068,703,840.22 from 1,092,555,719.72[198] - Construction in progress increased to 170,684,734.47 from 119,851,727.95[198] - Intangible assets grew to 172,988,645.37 from 165,489,853.23[198] - Deferred tax assets increased to 52,147,418.85 from 48,319,829.30[198] - Total non-current assets rose to 1,630,551,142.25 from 1,492,123,966.45[198] - Total assets increased to 4,807,656,211.82 from 4,663,579,989.81[198] - Current liabilities increased to 363,365,589.48 from 294,909,140.99[198] - Short-term borrowings stood at 100,065,000.00[198] Products and Market Position - The company's main products include Vitamin B6, Vitamin B1, Biotin, Folic Acid, Vitamin D3, and Vitamin E powder, primarily used in feed, pharmaceuticals, and food industries[8] - The company has established stable partnerships with thousands of customers, with domestic sales covering all provinces and international sales focusing on Europe, America, and Asia[8] - The company's B-vitamin products are water-soluble and mainly participate in enzyme system activities as coenzymes or cofactors[8] - The company's business is divided into three major segments: B-vitamins, other vitamins, and fine chemical products[8] - The company's global competitiveness is strong, with a diverse product portfolio including Vitamin B6, B1, biotin, folic acid, and other fine chemical products like ABL[21] - The company holds a leading global market share in Vitamin B6 and Vitamin B1, and is in the top tier for biotin and folic acid products[62] - The company has a well-established sales and service network, with products sold in Asia, Europe, North America, South America, Oceania, and Africa[68] Research and Development - The company's R&D efforts are supported by its subsidiary Shanghai Bonasain and its technology center, focusing on product optimization and new product development[66] - R&D expenses increased by 3.58% to 38,417,883.89 RMB[80] - Internal R&D expenditures are classified into research and development phases, with research phase expenses expensed as incurred and development phase expenses capitalized if specific criteria are met[127] Environmental and Social Responsibility - The company has a robust environmental protection system, including wastewater treatment, waste gas management, and hazardous waste treatment facilities[67] - The company has established a comprehensive management system, including quality, environmental, and occupational health and safety management systems, with certifications such as FDA, CEP, and ISO standards[65] - The company's emissions of particulate matter, SO2, and NOX are within the permissible limits, with no instances of exceeding the standards[132] - The company has invested 250,000 yuan in poverty alleviation and rural revitalization projects, benefiting approximately 1,000 people through educational support[137] - The company operates 5 wastewater pretreatment workshops, 3 sewage treatment stations, 2 sets of waste gas treatment systems, and 1 hazardous waste treatment center, all of which are functioning stably[133] - The company has not received any environmental penalties during the reporting period due to non-compliance or inadequate monitoring[133] - The company's VOCs emissions are 12.05mg/m³, which is significantly below the standard limit of 100mg/m³, with an annual emission of 87.36t[152] - CODcr emissions are 39.2mg/m³, below the final direct discharge standard of 60mg/L, with an annual emission of 119.8t[152] - Ammonia nitrogen emissions are 0.84mg/m³, well below the final direct discharge standard of 8mg/L, with an annual emission of 16.17t[152] - Particulate matter emissions from the thermal power plant are 1.97mg/m³, below the standard limit of 10mg/m³, with an annual emission of 10.18t[152] - SO₂ emissions from the thermal power plant are 11.82mg/m³, below the standard limit of 35mg/m³, with an annual emission of 10.72t[152] - NOX emissions from the thermal power plant are 23.73mg/m³, below the standard limit of 50mg/m³, with an annual emission of 50.89t[152] - The company has implemented energy-saving measures, including new equipment and technologies, resulting in a reduction in energy consumption per unit of main products[158] - The company has established a comprehensive environmental management system and passed environmental management system certification[157] - The company conducts regular environmental monitoring using both manual and online methods, with data uploaded in real-time to environmental authorities[155] - The company has developed an emergency response plan for environmental incidents, which was filed with the local environmental bureau in April 2021[154] Shareholder and Equity Information - The company distributed RMB -310,823,800.00 to shareholders during the period[19] - Total owner's equity increased by RMB 405,522,820.10, with retained earnings growing by RMB 400,554,808.56[19] - Owner's equity at the end of the period was RMB 4,082,082,011.58, with a capital reserve of RMB 1,981,933,320.43[25] - Comprehensive income for the period was RMB 401,248,794.80, contributing to the increase in owner's equity[25] - The company's total registered capital is RMB 437.78 million, with a total share capital of 437.78 million shares, each with a par value of RMB 1[34] - The company has seven subsidiaries included in its consolidated financial statements, such as Lepingshi Tianxin Thermal Power Co., Ltd. and Shanghai Bonasain Pharmaceutical R&D Co., Ltd[35] - The company recorded a total of 4,968,011.54 in equity-based compensation for the period[43] - The total equity balance at the end of the period was 2,314,914,198.45[45] - Comprehensive income for the period totaled 400,554,808.56 RMB[46] - Owner's capital contributions and reductions amounted to 4,968,011.54 RMB, primarily from share-based payments[46] - The ending balance for the period was 2,304,976,059.61 RMB[46] - The beginning balance of owner's equity was 4,063,022,747.23 RMB[48] - Total comprehensive income for the period was 344,607,638.98 RMB[48] - Owner's capital contributions and reductions were 4,968,011.54 RMB, mainly from share-based payments[48] - Profit distribution included a reduction of 310,823,800.00 RMB[48] - The beginning balance of consolidated owner's equity was 4,057,981,639.72 RMB[56] - Total comprehensive income for the period was 329,956,160.32 RMB[56] - Owner's capital contributions and reductions were 4,968,011.54 RMB[56] - The largest shareholder, Xu Jiangnan, holds 203,603,970 restricted shares with a lock-up period until January 11, 2026[195] - The second-largest shareholder, Xu Jing, holds 59,110,830 restricted shares with the same lock-up period[195] - The company's largest shareholder, Xu Jiangnan, holds 203,603,970 shares, representing 46.51% of the total shares, all of which are restricted shares[150] - Xu Jing, the second-largest shareholder, holds 59,110,830 shares, accounting for 13.50% of the total shares, all of which are restricted shares[150] - Wang Guangtian, the third-largest shareholder, holds 56,803,200 shares, representing 12.98% of the total shares, all of which are restricted shares[150] - Qiu Qinyong, the fourth-largest shareholder, holds 35,502,000 shares, accounting for 8.11% of the total shares, all of which are restricted shares[150] - The company has committed to stabilizing its stock price within three years of listing by implementing a stock repurchase plan if the stock price falls below the net asset value per share for 20 consecutive trading days[145] - The controlling shareholder and actual controller have pledged to support the stock price stabilization plan by voting in favor of stock repurchase proposals and increasing their shareholdings if necessary[145] - The company has established a lock-up period of 36 months for shares held by certain entities, during which they cannot transfer or entrust others to manage the shares[142] - After the lock-up period, shareholders are allowed to reduce their holdings, but they must announce the reduction three trading days in advance and comply with relevant laws and regulations[142] - If the stock price falls below the issue price for 20 consecutive trading days within six months of listing, the lock-up period for certain shares will be automatically extended by at least six months[142] - The company has committed to avoiding competition with its subsidiaries and will transfer any competing business opportunities to the subsidiaries or third parties to eliminate potential conflicts[145] - The company has committed to not transferring or entrusting others to manage its directly or indirectly held shares before the IPO for 36 months from the listing date[164] - The company will strictly regulate related-party transactions with its wholly-owned, controlled subsidiaries, and other entities under actual control[164] - The company will follow fair, just, and open principles for unavoidable related-party transactions, signing relevant agreements and fulfilling decision-making and disclosure obligations[164] - The company ensures that all transactions with its subsidiaries and controlled entities will strictly follow market rules and commercial principles[164] - The company will avoid using its controlling shareholder status to harm the interests of the company and other shareholders through related-party transactions[164] - The company will not directly or indirectly borrow, occupy, or otherwise misappropriate the company's funds or assets[164] - The company has disclosed all equity or interests held directly or indirectly in other enterprises or economic organizations[165] - The company and its controlled entities will not engage in any business activities that compete directly or indirectly with the company's main business[165] - The company will ensure that its controlled entities do not seek commercial opportunities belonging to the company or its subsidiaries[165] - The company will take necessary measures to correct and remedy any violations of the above commitments and bear compensation for any losses caused[165] - The company has committed to avoiding any business activities that directly or indirectly compete with Tianxin Pharmaceutical, including ceasing sales of similar products and not engaging in any competitive business opportunities[167] - The company will not provide business qualifications, operating licenses, proprietary technologies, sales channels, or customer information to any entities that compete with Tianxin Pharmaceutical[167] - The company will reduce and regulate related-party transactions with Tianxin Pharmaceutical, ensuring they are conducted at fair market prices and in compliance with legal and regulatory requirements[168] Legal and Compliance - The company has no significant litigation or arbitration matters during the reporting period[170] - The company and its controlling shareholders are not involved in any illegal activities or subject to penalties, and there are no significant debts overdue[170] Investments and Capital Expenditures - Investment in the first half of 2023 was RMB 104.5 million, a 1507.69% increase compared to the same period last year[96] - The company's subsidiary, Ningxia Tianxin Pharmaceutical Co., Ltd., is investing RMB 890 million in a fine chemical products and supporting thermal power project[99] - The company's trading financial assets decreased by 100% due to the redemption of financial products[93] - Other current assets decreased by 67.40% due to a reduction in VAT credits[93] - Construction in progress increased by 55.53% due to increased engineering investments[93] - Intangible assets grew by 77.43% due to the acquisition of new land use rights[93] - Other non-current assets increased by 180.98% due to prepayments for long-term

一、 2023年第二季度主要经营数据 1、主营业务分产品情况 证券代码：603235 证券简称：天新药业 公告编号：2023-020 江西天新药业股份有限公司 关于 2023 年第二季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司（以下简称"公司"） 2023 年第二季度经营数据（未经审计）公告如下： | 产品分类 | 2023 | 年 4-6 | 月收入 | 2022 | 年 4-6 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | --- | | 内销 | | 234,152,402.71 | | | 204,141,804.45 | | 14.70% | | 外销 | | 298,477,236.68 | | | 418,340,681.10 | | -28.65% | | 小计 | | 532,629,639. ...